| Autor: |
Maccora, Ilaria, Land, Preston, Miraldi Utz, Virginia, Angeles-Han, Sheila T |
| Předmět: |
|
| Zdroj: |
Expert Review of Clinical Immunology; Jul2023, Vol. 19 Issue 7, p689-692, 4p |
| Abstrakt: |
Expert consensus guidelines generally recommend a step-ladder approach to treat JIA-associated uveitis (JIA-U) with corticosteroids as first-line agent followed by steroid-sparing systemic treatment with methotrexate. American college of rheumatology guideline for the treatment of juvenile idiopathic arthritis: recommendations for nonpharmacologic therapies, medication monitoring, immunizations, and imaging. Keywords: Baricitinib; pediatric uveitis; JAK-inhibitor; JIA; tofacitinib; treatment; upadacitinib; Uveitis EN Baricitinib pediatric uveitis JAK-inhibitor JIA tofacitinib treatment upadacitinib Uveitis 689 692 4 07/10/23 20230701 NES 230701 1. In conclusion, JAK-I has shown to be effective for children with JIA and as potentially promising treatment of ocular inflammatory disease. [Extracted from the article] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
